The National Cancer Institute (NCI) is conducting a phase 2 clinical trial that aims to investigate the safety and efficacy of olaparib as a subsequent line therapy for patients with advanced solid tumors (including CCA) with IDH1 or IDH2 mutations (NCT03212274). Here, IDH1 is linked to cholangiocarcinoma.